Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark (A.P.).
Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark (S.M.N.).
Ann Intern Med. 2023 Sep;176(9):1181-1189. doi: 10.7326/M23-0192. Epub 2023 Aug 15.
Weight gain and hypertension are well known adverse effects of treatment with high-dose glucocorticoids.
To evaluate the effects of 2 years of low-dose glucocorticoid treatment in rheumatoid arthritis (RA).
Pooled analysis of 5 randomized controlled trials with 2-year interventions allowing concomitant treatment with disease-modifying antirheumatic drugs.
12 countries in Europe.
Early and established RA.
Glucocorticoids at 7.5 mg or less prednisone equivalent per day.
Coprimary end points were differences in change from baseline in body weight and mean arterial pressure after 2 years in intention-to-treat analyses. Difference in the change of number of antihypertensive drugs after 2 years was a secondary end point. Subgroup and sensitivity analyses were done to assess the robustness of primary findings.
A total of 1112 participants were included (mean age, 61.4 years [SD, 14.5]; 68% women). Both groups gained weight in 2 years, but glucocorticoids led, on average, to 1.1 kg (95% CI, 0.4 to 1.8 kg; < 0.001) more weight gain than the control treatment. Mean arterial pressure increased by about 2 mm Hg in both groups, with a between-group difference of -0.4 mm Hg (CI, -3.0 to 2.2 mm Hg; = 0.187). These results were consistent in sensitivity and subgroup analyses. Most patients did not change the number of antihypertensive drugs, and there was no evidence of differences between groups.
Body composition was not assessed, and generalizability to non-European regions may be limited.
This study provides robust evidence that low-dose glucocorticoids, received over 2 years for the treatment of RA, increase weight by about 1 kg but do not increase blood pressure.
None.
体重增加和高血压是大剂量糖皮质激素治疗的已知不良反应。
评估类风湿关节炎(RA)患者接受 2 年低剂量糖皮质激素治疗的效果。
对 5 项为期 2 年的随机对照试验进行汇总分析,这些试验允许同时使用改善病情的抗风湿药物进行治疗。
欧洲 12 个国家。
早期和确诊的 RA。
每天 7.5 毫克或更少的泼尼松等效剂量的糖皮质激素。
主要终点是意向治疗分析中,治疗 2 年后,体重和平均动脉压从基线的变化差异。次要终点是治疗 2 年后降压药数量变化的差异。进行了亚组和敏感性分析,以评估主要发现的稳健性。
共纳入 1112 名参与者(平均年龄 61.4 岁[SD,14.5];68%为女性)。两组在 2 年内体重均增加,但与对照组相比,糖皮质激素组的平均体重增加了 1.1 公斤(95%CI,0.4 至 1.8 公斤;<0.001)。两组的平均动脉压均升高约 2mmHg,组间差异为-0.4mmHg(CI,-3.0 至 2.2mmHg;=0.187)。这些结果在敏感性和亚组分析中是一致的。大多数患者未改变降压药的数量,且两组之间无差异证据。
未评估身体成分,其结果可能无法推广到非欧洲地区。
本研究提供了有力证据,表明在治疗 RA 时,2 年内接受低剂量糖皮质激素治疗会使体重增加约 1 公斤,但不会增加血压。
无。